G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: Results of A-HeFT

JACC: Heart Failure

Volumn 2, Issue 6, 2014, Pages 551-557

  McNamara, Dennis M ^a   Taylor, Anne L ^b   Tam, S William ^c   Worcel, Manuel ^c   Yancy, Clyde W ^d   Hanley Yanez, Karen ^a   Cohn, Jay N ^e   Feldman, Arthur M ^f  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c Northwestern University ^*  (France)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Outcomes; Pharmacogenetics; Race

Indexed keywords

G PROTEIN BETA 3 SUBUNIT PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; PLACEBO; UNCLASSIFIED DRUG; DRUG COMBINATION; GUANINE NUCLEOTIDE BINDING PROTEIN (G PROTEIN), BETA POLYPEPTIDE 3, HUMAN; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; HYDRALAZINE; ISOSORBIDE DINITRATE; VASODILATOR AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; AFRICAN AMERICAN; ANALYSIS OF VARIANCE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; GENETICS; HEART LEFT VENTRICLE FUNCTION; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

AFRICAN AMERICANS; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; GENOTYPE; HEART FAILURE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; LENGTH OF STAY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; QUALITY OF LIFE; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84926150050     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.04.016     Document Type: Article

References (37)

1. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. NEngl J Med 1986, 314:1547-1552.
2. Cohn J.N., Johnson G., Ziesche S., et al. Acomparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. NEngl J Med 1991, 325:303-310.
3. Carson P., Ziesche S., Johnson G., Cohn J.N. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials: Vasodilator-Heart Failure Trial Study Group. JCard Fail 1999, 5:178-187.
4. Taylor A.L. The African-American Heart Failure Trial (A-HeFT): rationale and methodology. JCard Fail 2003, 9(Suppl Nitric Oxide):S216-S219.
5. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. NEngl J Med 2004, 351:2049-2057.
6. Meirhaeghe A., Bauters C., Helbecque N., et al. The human G-protein beta3 subunit C825T polymorphism is associated with coronary artery vasoconstriction. Eur Heart J 2001, 22:845-848.
7. Siffert W., Rosskopf D., Siffert G., et al. Association of a human G-protein β3 subunit variant with hypertension. Nat Genet 1998, 18:45-48.
8. Siffert W. G-protein β3 subunit 825T allele and hypertension. Curr Hypertens Rep 2003, 5:47-53.
9. Schunkert H., Hense H.W., Doring A., et al. Association between a polymorphism in the G-protein β3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998, 32:510-513.
10. Siffert W., Forster P., Jockel K.H., et al. Worldwide ethnic distribution of the G-protein β3 subunit 825T allele and its association with obesity in Caucasian, Chinese and black African individuals. JAm Soc Nephrol 1999, 10:1921-1930.
11. McNamara D.M., Holubkov R., Janosko K., et al. Pharmacogenetic interactions between β-blocker therapy and the angiotensin converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001, 103:1644-1648.
12. McNamara D.M., Holubkov R., Postava L., et al. Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation 2003, 107:1598-1602.
13. Cohn J.N., Tam S.W., Anand I.S., et al. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail 2007, 13:331-339.
14. Rosskopf D., Busch S., Manthey I., Siffert W. G-protein gene: structure, promoter and additional polymorphisms. Hypertension 2000, 36:33-41.
15. Rosskopf D., Manthey, Siffert W. Identification and ethnic distribution of major haplotypes in the gene GNB3 encoding the G-protein β3 subunit. Pharmacogenetics 2002, 12:209-220.
16. Siffert W., Rosskopf D., Moritz A., et al. Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. JClin Invest 1995, 96:759-766.
17. Siffert W. Gprotein β3 subunit 825T allele, hypertension, obesity, and diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1298-1306.
18. Poch E., Gonzalez D., Gomez-Angelats E., et al. G-protein β3 subunit gene variant and left ventricular hypertrophy in essential hypertension. Hypertension 2000, 35:214-218.
19. Young J.H., Chang Y.P., Kim J.D., et al. Differential susceptibility to hypertension is due to selection during the out-of-Africa expansion. PLoS Genet 2005, 1:e82.
20. Nurnberger J., Dammer S., Mitchell A., et al. Effect of the C825T polymorphism of the G protein β3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin Pharmacol Ther 2003, 74:53-60.
21. Naber C., Baumgart D., Heusch G., et al. Role of eNOS Glu289Asp variant on the GNB3825T allele dependent determination of α-adrenergic coronary constriction. Pharmacogenetics 2003, 13:279-284.
22. Baumgart D., Naber C., Haude M., et al. Gprotein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation. Circ Res 1999, 85:965-969.
23. Goldlust I.S., Hermetz K.E., Catalano L.M., et al. Mouse model implicates GNB3 duplication in a childhood obesity syndrome. Proc Natl Acad Sci US A 2013, 110:14990-14994.
24. Xia Q., Grant S.F. The genetics of human obesity. Ann N Y Acad Sci 2013, 1281:178-190.
25. Levy D., Ehret G.B., Rice K., et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41:677-687.
26. Wenzel R., Siffert W., Bruck H., et al. Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. Pharmacogenetics 2002, 12:489-495.
27. Mitchell A., Bührmann S., Seifert A., et al. Venous response to nitroglycerin is enhanced in young, healthy carriers of the 825T allele of the G protein beta3 subunit gene (GNB3). Clin Pharmacol Ther 2003, 74:499-504.
28. Sperling H., Eisenhardt A., Virchow S., et al. Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study. JUrol 2003, 169:1048-1051.
29. Sekine A., Tanabe N., Sugiura T., et al. Polymorphism of the G protein β3 subunit gene influences the efficacy of sildenafil in patients with pulmonary hypertension. Intern Med 2014, 53:291-297.
30. Mitchell A., Pace M., Nürnberger J., et al. Insulin-mediated venodilation is impaired in young, healthy carriers of the 825T allele of theG-protein beta3 subunit gene (GNB3). Clin Pharmacol Ther 2005, 77:495-502.
31. Daimon M., Sato H., Kaino W., et al. Association of the G-protein β3 subunit gene polymorphism with the incidence of cardiovascular disease independent of hypertension: the Funagata study. JHum Hypertens 2013, 27:612-616.
32. Casiglia E., Tikhonoff V., Boschetti G., et al. The C825T GNB3 polymorphism, independent of blood pressure, predicts cerebrovascular risk at a population level. Am J Hypertens 2012, 25:451-457.
33. Chemello D., Rohde L.E., Santos K.G., et al. Genetic polymorphisms of the adrenergic system and implantable cardioverter-defibrillator therapies in patients with heart failure. Europace 2010, 12:686-691.
34. McNamara D.M., Tam S.W., Sabolinski M.L., et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. JCard Fail 2009, 15:191-198.
35. McNamara D.M., Tam S.W., Sabolinski M.L., et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. JAm Coll Cardiol 2006, 48:1277-1282.
36. Bloche M.G. Race-based therapeutics. NEngl J Med 2004, 351:2035-2037.
37. Cole R.T., Kalogeropoulos A.P., Georgiopoulou V.V., et al. Hydralazine and isosorbide dinitrate in heartfailure: historical perspective, mechanisms, and future directions. Circulation 2011, 123:2414-2422.